In this interview, IP Group’s CEO, Greg Smith, highlights the potentially transformational implications of Pfizer’s acquisition of Metsera (for up to $7.3bn, of which $4.9bn is in upfront cash), whose MET-097 anti-obesity drug is progressing through Phase II. IP Group is entitled to low single‑digit royalties from a number of Metsera compounds, including MET‑097. EvaluatePharma forecasts that MET-097 could generate $9.2bn in non-risk-adjusted revenue by 2032, implying significant royalty streams to IP Group if commercialisation is successful. Greg reiterates confidence in management’s target of achieving at least £250m of exits by end‑2027 (excluding Oxford Nanopore), citing Monolith’s sale to CoreWeave and Hinge Health’s NYSE IPO (where IP Group achieved roughly a 50x return) as evidence. Greg also discusses progress on securing third‑party capital through UK pension funds and Mansion House initiatives, with management expecting to announce a new mandate by full‑year results, while highlighting portfolio momentum across AI, genomics, quantum and cleantech sectors.

Listen on your preferred podcast player below:

• Apple Podcast
• Spotify
• YouTube
• Zencastr

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.

In this interview, IP Group’s CEO, Greg Smith, highlights the potentially transformational implications of Pfizer’s acquisition of Metsera (for up to $7.3bn, of which $4.9bn is in upfront cash), whose MET-097 anti-obesity drug is progressing through Phase II. IP Group is entitled to low single‑digit royalties from a number of Metsera compounds, including MET‑097. EvaluatePharma forecasts that MET-097 could generate $9.2bn in non-risk-adjusted revenue by 2032, implying significant royalty streams to IP Group if commercialisation is successful. Greg reiterates confidence in management’s target of achieving at least £250m of exits by end‑2027 (excluding Oxford Nanopore), citing Monolith’s sale to CoreWeave and Hinge Health’s NYSE IPO (where IP Group achieved roughly a 50x return) as evidence. Greg also discusses progress on securing third‑party capital through UK pension funds and Mansion House initiatives, with management expecting to announce a new mandate by full‑year results, while highlighting portfolio momentum across AI, genomics, quantum and cleantech sectors. IP Group helps to create, build and support IP-based companies internationally. It focuses on companies that meaningfully contribute to regenerative (renewable), healthier (life sciences) and tech-enriched (deep tech) futures.